Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar
04 déc. 2023 07h09 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Adamas One Joins Webull’s Corporate Connect Service
07 nov. 2023 09h00 HE
|
Adamas One Corp.
SCOTTSDALE, Ariz., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Adamas One Corp. (Nasdaq: JEWL) (“Adamas One,” “Adamas” or the “Company”), The Original Lab-Grown Diamond Company™, a high-tech company that...
Webull Launches in the United Kingdom
12 juil. 2023 03h00 HE
|
Webull Corporation
LONDON, July 12, 2023 (GLOBE NEWSWIRE) -- Webull Corporation (“Webull”), the owner of the popular Webull trading platform, today announced the launch of its retail brokerage services in the UK....
Alarum Joins Webull Corporate Connect Service Platform
16 juin 2023 08h30 HE
|
Alarum Technologies Ltd.
TEL AVIV, Israel, June 16, 2023 (GLOBE NEWSWIRE) -- Alarum Technologies Ltd. (Nasdaq, TASE: ALAR) (“Alarum” or the “Company”), a global provider of enterprise and consumers internet access...
Silo Pharma Announces Participation on Webull Corporate Communications Service Platform
02 juin 2023 08h50 HE
|
Silo Pharma, Inc.
Webull’s investor community can now access the SILO profile for real-time data and investor communications ENGLEWOOD CLIFFS, NJ, June 02, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq:...
Tiziana Life Sciences Announces Participation on the Webull Corporate Communications Service Platform
23 mai 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, May 23, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
OKYO Pharma Now Participating on the Webull Corporate Communications Service Platform
11 mai 2023 07h00 HE
|
OKYO Pharma LTD
LONDON and NEW YORK, May 11, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye...